Contribution of pre-existing neoantigen-specific T cells to a durable complete response after tumor-pulsed dendritic cell vaccine plus nivolumab therapy in a patient with metastatic salivary duct carcinoma.　Ichimiya S, Fujimura A, Masuda M, Masuda S, Yasumatsu R, Umebayashi M, et al.　Immunol Invest. 2021 Sep 5:1-17. doi: 10.1080/08820139.
2021.1973491.

Efficacy of Intranodal Neoantigen Peptide-pulsed Dendritic Cell Vaccine Monotherapy in Patients With Advanced Solid Tumors: A Retrospective Analysis. Morisaki T, Morisaki T, Kubo M, Onishi H, Hirano T, Morisaki S, et al. Anticancer Res. 2021 Aug;41(8):4101-4115. doi: 10.21873/anticanres.15213.

Neoantigens elicit T cell responses in breast cancer. Morisaki T, Kubo M, Umebayashi M, Yew PY, Yoshimura S, Park JH, et al. Sci Rep. 2021 Jun 30;11(1):13590. doi: 10.1038/s41598-021-91358-1.

Intranodal Administration of Neoantigen Peptide-loaded Dendritic Cell Vaccine Elicits Epitope-specific T Cell Responses and Clinical Effects in a Patient with Chemorefractory Ovarian Cancer with Malignant Ascites. Morisaki T, Hikichi T, Onishi H, Morisaki T, Kubo M, Hirano T, et, al. Immunol Invest. 2020; 1-18. doi: 10.1080/08820139.2020.1778721.

The road map of cancer precision medicine with the innovation of advanced cancer detection technology and personalized immunotherapy. Low SK, Nakamura Y. Jpn J Clin Oncol. 2019;49(7):596-603.

Identification of neoantigen-specific T cells and their targets: implications for immunotherapy of head and neck squamous cell carcinoma. Ren L, Leisegang M, Deng B, Matsuda T, Kiyotani K, Kato T, et al. Oncoimmunology. 2019;8(4):e1568813.

Induction of Neoantigen-Specific Cytotoxic T Cells and Construction of T-cell Receptor-Engineered T Cells for Ovarian Cancer. Matsuda T, Leisegang M, Park JH, Ren L, Kato T, Ikeda Y, et al. Clin Cancer Res. 2018;24(21):5357-5367.

Effective screening of T cells recognizing neoantigens and construction of T-cell receptor-engineered T cells.　 Kato T, Matsuda T, Ikeda Y, Park JH, Leisegang M, Yoshimura S, Hikichi T, et. al. Oncotarget. 2018 Jan 13;9(13):11009-11019.

Integrated analysis of somatic mutations and immune microenvironment in malignant pleural mesothelioma. Kiyotani K, Park JH, Inoue H, Husain A, Olugbile S, Zewde M, Nakamura Y and Vigneswaran W. T. OncoImmunology. 2017;doi.org/10.1080/2162402X.2016.1278330.

Integrated analysis of somatic mutations and immune microenvironment of multiple regions in breast cancers. Kato T, Park JH, Kiyotani K, Ikeda Y, Miyoshi Y, Nakamura Y. Oncotarget. 2017;8(37):62029-62038.

Eradication of large solid tumors by gene therapy with a T cell receptor targeting a single cancerspecific point mutation. M Leisegang, B Engels, K Schreiber, PY Yew, K Kiyotani, C Idel, et al. Clinical Cancer Research. 2015; 2361

A Pilot Study of the Adverse Events Caused by the Combined Use of Bevacizumab and Vascular Endothelial Growth Factor Receptor-Targeted Vaccination for Patients with a Malignant Glioma. Tamura R, Morimoto Y, Sato M, Hikichi T, Yoshida K, Toda M, et al. Vaccines (Basel). 2020 Sep 2;8(3):498. doi: 10.3390/vaccines8030498.

A VEGF receptor vaccine demonstrates preliminary efficacy in neurofibromatosis type 2. Tamura R, Fujioka M, Morimoto Y, Ohara K, Kosugi K, Oishi Y, et, al. Nature Communications 2019; 10(1):5758.

A phase I/Ib study of OTSGC-A24 combined peptide vaccine in advanced gastric cancer. Sundar R, Rha SY, Yamaue H, Katsuda M, Kono K, Kim HS, et al. BMC Cancer. 2018; 27;18(1):332.

Phase I clinical trial of a five-peptide cancer vaccine combined with cyclophosphamide in advanced solid tumors. Murahashi M, Hijikata Y, Yamada K, Tanaka Y, Kishimoto J, Inoue H, et al. Clin Immunol. 2016; 166-167:48-58.

Phase II clinical trial of multiple peptide vaccination for advanced head and neck cancer patients revealed induction of immune responses and improved OS. Y Yoshitake, D Fukuma, A Yuno, M Hirayama, H Nakayama, T Tanaka, et al. Clin Cancer Res. 2015; 15;21(2):312-21.

A phase I study of combination vaccine treatment of five therapeutic epitope-peptides for metastatic colorectal cancer; safety, immunological response, and clinical outcome. S Hazama, Y Nakamura, H Takenouchi, N Suzuki, R Tsunedomi, Y Inoue, et al. J Transl Med. 2014; 10;12:63.

Phase I clinical study of multiple epitope peptide vaccine combined with chemoradiation therapy in esophageal cancer patients. H Iinuma, R Fukushima, T Inaba, J Tamura, T Inoue, E Ogawa, et al. J Transl Med. 2014; 3;12:84.

A phase ΙI study of five peptides combination with oxaliplatin-based chemotherapy as a first-line therapy for advanced colorectal cancer (FXV study). S Hazama, Y Nakamura, H Tanaka, K Hirakawa, K Tahara, R Shimizu, et al. J Transl Med. 2014; 30;12:108.

Clinical trial of a 7-peptide cocktail vaccine with oral chemotherapy for patients with metastatic colorectal cancer.　Okuno K, Sugiura F, Inoue K, Sukegawa Y. Anticancer Res. 2014; 34(6):3045-52.

Predictive biomarkers for the outcome of vaccination of five therapeutic epitope peptides for colorectal cancer. Hazama S, Takenouchi H, Tsunedomi R, Iida M, Suzuki N, Iizuka N, et al. Anticancer Res. 2014; 34(8):4201-5.

A phase I clinical trial of vaccination with KIF20A-derived peptide in combination with gemcitabine for patients with advanced pancreatic cancer. Suzuki N, Hazama S, Ueno T, Matsui H, Shindo Y, Iida M, et al. J Immunother. 2014; 37(1):36-42.

Phase I clinical trial of multiple-peptide vaccination for patients with advanced biliary tract cancer. Aruga A, Takeshita N, Kotera Y, Okuyama R, Matsushita N, Ohta T, et al. J Transl Med. 2014; 7;12:61.

Vaccination of biliary tract cancer patients with four peptides derived from cancer-testis antigens. Aruga A. Oncoimmunology. 2013; 1;2(7)

Immunological responses to a multi-peptide vaccine targeting cancer-testis antigens and VEGFRs in advanced pancreatic cancer patients. Okuyama R, Aruga A, Hatori T, Takeda K, Yamamoto M. Oncoimmunology. 2013; 1;2(11)

Phase I clinical trial of a peptide vaccine combined with tegafur-uracil plus leucovorin for treatment of advanced or recurrent colorectal cancer. Matsushita N, Aruga A, Inoue Y, Kotera Y, Takeda K, Yamamoto M. Oncol Rep. 2013; 29(3):951-9.

Phase I/II clinical trial using HLA-A24-restricted peptide vaccine derived from KIF20A for patients with advanced pancreatic cancer. Asahara S, Takeda K, Yamao K, Maguchi H, Yamaue H. J Transl Med. 2013; 16;11:291.

Multiple therapeutic peptide vaccines consisting of combined novel cancer testis antigens and anti-angiogenic peptides for patients with non-small cell lung cancer. Suzuki H, Fukuhara M, Yamaura T, Mutoh S, Okabe N, Yaginuma H, et al. J Transl Med. 2013; 11;11:97.

Phase I clinical trial of human vascular endothelial growth factor receptor 1 peptide vaccines for patients with metastatic renal cell carcinoma. Yoshimura K, Minami T, Nozawa M, Uemura H. Br J Cancer. 2013; 2;108(6):1260-6.

Long-term Vaccination with Multiple Peptides Derived from Cancer-Testis Antigens Can Maintain a Specific T-cell Response and Achieve Disease Stability in Advanced Biliary Tract Cancer. Aruga A, Takeshita N, Kotera Y, Okuyama R, Matsushita N, Ohta T, et al. Clin Cancer Res. 2013; 15;19(8):2224-31.

Multicenter, phase II clinical trial of cancer vaccination for advanced esophageal cancer with three peptides derived from novel cancer-testis antigens. K Kono, H Iinuma, Y Akutsu, H Tanaka, N Hayashi, Y Uchikado, et al. J Transl Med. 2012; 9;10:141.

Cancer peptide vaccine therapy developed from oncoantigens identified through genome-wide expression profile analysis for bladder cancer. W Obara, R Ohsawa, M Kanehira, R Takata, T Tsunoda, K Yoshida, et al. Jpn J Clin Oncol. 2012; 42(7):591-600.

Phase I/II study of S1 plus cisplatin combined with peptide vaccines for human vascular endothelial growth factor receptor 1 and 2 in patients with advanced gastric cancer. T Masuzawa, Y Fujiwara, K Okada, A Nakamura, S Takiguchi, K Nakajima, et al. Int J Oncol. 2012; 41(4):1297-304.

Recent Advances in Active Specific Cancer Vaccine Treatment for Colorectal Cancer. K Okuno, F Sugiura, K Itoh, K Yoshida, T Tsunoda, Y Nakamura, Curr Pharm Biotechnol. 2012; 13(8):1439-45.

Significant clinical response of advanced colon cancer to peptide vaccine therapy: a case report. S Yasuda, I Tsuchiya, K Okada, A Tanaka, T Suzuki, S Sadahiro, et al. Tokai J Exp Clin Med. 2012; 20;37(2):57-61.

Phase I clinical trial of a novel peptide vaccine in combination with UFT/LV for metastatic colorectal cancer. K Okuno, F Sugiura, J Hida, T Tokoro, E Ishimaru, Y Sukegawa, et al. Exp Ther Med. 2011; 2(1):73-79.

Vaccination with peptides derived from cancer-testis antigens in combination with CpG-7909 elicits strong specific CD8+ T cell response in patients with metastatic esophageal squamous cell carcinoma. Iwahashi M, Katsuda M, Nakamori M, Nakamura M, Naka T, Ojima T, et al. Cancer Sci. 2010; 101(12):2510-7.

Vaccination with multiple peptides derived from novel cancer‐testis antigens can induce specific T‐cell responses and clinical responses in advanced esophageal cancer. K Kono, Y Mizukami, Y Daigo, A Takano, K Masuda, K Yoshida, et al. Cancer Sci. 2009; 100(8):1502-9.

Phase I clinical trial using peptide vaccine for human vascular endothelial growth factor receptor 2 in combination with gemcitabine for patients with advanced pancreatic cancer. M Miyazawa, R Ohsawa, T Tsunoda, S Hirono, M Kawai, M Tani, et al. Cancer Sci. 2010; 101(2):433-9.

Detection of novel cancer‐testis antigen‐specific T‐cell responses in TIL, regional lymph nodes, and PBL in patients with esophageal squamous cell carcinoma., Y Mizukami, K Kono, Y Daigo, A Takano, T Tsunoda, Y Kawaguchi, et al. Cancer Sci. 2010; 101(2):433-9.

Identification of CDCA1‐derived long peptides bearing both CD4+ and CD8+ T‐cell epitopes: CDCA1‐specific CD4+ T‐cell immunity in cancer patients. Y Tomita, A Yuno, H Tsukamoto, S Senju, S Yoshimura, R Osawa, et al. Int J Cancer. 2014; 15;134(2):352-66.

Identification of immunogenic LY6K long peptide encompassing both CD4+ and CD8+ T-cell epitopes and eliciting CD4+ T-cell immunity in patients with malignant disease. Y Tomita, A Yuno, H Tsukamoto, S Senju, Y Kuroda, M Hirayama, et al. Oncoimmunology. 2014; 27;3:e28100.

Identification of promiscuous KIF20A long peptides bearing both CD4+ and CD8+ T-cell epitopes: KIF20A-specific CD4+ T-cell immunity in patients with malignant tumor. Y Tomita, A Yuno, H Tsukamoto, S Senju, Y Kuroda, M Hirayama, A Irie, et al. Clin Cancer Res. 2013; 15;19(16):4508-20.

Identification of HLA-A24-restricted novel T Cell epitope peptides derived from P-cadherin and kinesin family member 20A. R Osawa, T Tsunoda, S Yoshimura, T Watanabe, M Miyazawa, M Tani, et al. J Biomed Biotechnol. 2012; 2012:848042.

Identification of HLA-A2-restricted CTL epitopes of a novel tumour-associated antigen, KIF20A, overexpressed in pancreatic cancer. K Imai, S Hirata, A Irie, S Senju, Y Ikuta, K Yokomine, M Harao, M Inoue, et al. Br J Cancer. 2011; 18;104(2):300-7.

HLA‐A2‐restricted CTL epitopes of a novel lung cancer‐associated cancer testis antigen, cell division cycle associated 1, can induce tumor‐reactive CTL. M Harao, S Hirata, A Irie, S Senju, T Nakatsura, H Komori, Y Ikuta, et al. Int J Cancer. 2008; 1;123(11):2616-25.

Identification of human leukocyte antigen‐A24‐restricted epitope peptides derived from gene products upregulated in lung and esophageal cancers as novel targets for immunotherapy. T Suda, T Tsunoda, Y Daigo, Y Nakamura, H Tahara. Cancer Sci. 2007; 98(11):1803-8

Involvement of upregulation of DEPDC1 (DEP domain containing 1) in bladder carcinogenesis. Kanehira M, Harada Y, Takata R, Shuin T, Miki T, Fujioka T, et al. Oncogene. 2007; 27;26(44):6448-55.

Oncogenic role of MPHOSPH1, a cancer-testis antigen specific to human bladder cancer. Kanehira M, Katagiri T, Shimo A, Takata R, Shuin T, Miki T, et al. Cancer Res. 2007; 1;67(7):3276-85.

Cancer-testis antigen lymphocyte antigen 6 complex locus K is a serologic biomarker and a therapeutic target for lung and esophageal carcinomas. Ishikawa N, Takano A, Yasui W, Inai K, Nishimura H, Ito H, et al. Cancer Res. 2007; 15;67(24):11601-11.

Inhibition of tumor growth with antiangiogenic cancer vaccine using epitope peptides derived from human vascular endothelial growth factor receptor 1. Ishizaki H, Tsunoda T, Wada S, Yamauchi M, Shibuya M, Tahara H. Clin Cancer Res. 2006; 1;12(19):5841-9.

Activation of CDCA1-KNTC2, members of centromere protein complex, involved in pulmonary carcinogenesis. Hayama S, Daigo Y, Kato T, Ishikawa N, Yamabuki T, Miyamoto M, et al. Cancer Res. 2006; 1;66(21):10339-48.

Identification of TOMM34, which shows elevated expression in the majority of human colon cancers, as a novel drug target. Shimokawa T, Matsushima S, Tsunoda T, Tahara H, Nakamura Y, Furukawa Y. Int J Oncol. 2006; 29(2):381-6.

Rationale for antiangiogenic cancer therapy with vaccination using epitope peptides derived from human vascular endothelial growth factor receptor 2. Wada S, Tsunoda T, Baba T, Primus FJ, Kuwano H, Shibuya M, et al. Cancer Res. 2005; 1;65(11):4939-46.

Down-regulation of RAB6KIFL/KIF20A, a kinesin involved with membrane trafficking of discs large homologue 5, can attenuate growth of pancreatic cancer cell. Taniuchi K, Nakagawa H, Nakamura T, Eguchi H, Ohigashi H, Ishikawa O, et al. Cancer Res. 2005; 1;65(1):105-12.

A novel oncoprotein RNF43 functions in an autocrine manner in colorectal cancer. R Yagyu, Y Furukawa, YM Lin, T Shimokawa, T Yamamura, Y Nakamura, Int J Oncol. 2004; 25(5):1343-8.

Clinical Trial of a Cancer Vaccine Targeting VEGF and KIF20A in Advanced Biliary Tract Cancer. Murahashi M, Tsuruta T, Yamada K, Hijikata Y, Ogata H, Kishimoto J, et al. Anticancer Res. 2021 Mar;41(3):1485-1496. doi: 10.21873/anticanres.
14907.

Exploratory open-label clinical study to determine the S-588410 cancer peptide vaccine-induced tumor-infiltrating lymphocytes and changes in the tumor microenvironment in esophageal cancer patients. Daiko H, Marafioti T, Fujiwara T, Shirakawa Y, Nakatsura Y, Kato K, et, al. Cancer Immunol Immunother. 2020; doi: 10.1007/s00262-020-02619-3.

Significant differences in T cell receptor repertoires in lung adenocarcinomas with and without epidermal growth factor receptor mutations. Miyauchi E, Matsuda T, Kiyotani K, Low SK, Hsu YW, Tsukita Y, et al. Cancer Sci. 2019;110(3):867-874./

Bladder cancer-associated cancer-testis antigen-derived long peptides encompassing both CTL and promiscuous HLA class II-restricted Th cell epitopes induced CD4+ T cells expressing converged T-cell receptor genes in vitro. Tsuruta, M., Ueda, S., Yew, P.Y., Fukuda, I., Yoshimura, S., Kishi, H., et al. Oncoimmunology. 2018;7(4):e1415687.

Similarity and difference in tumor-infiltrating lymphocytes in original tumor tissues and those of in vitro expanded populations in head and neck cancer. Lili Ren, Tatsuo Matsuda, Boya Deng, Kazuma Kiyotani, Taigo Kato, Jae-Hyun Park, et al. Oncotarget. 2017;9(3):3805-3814.

Quantitative analysis and clonal characterization of T-cell receptor β repertoires in patients with advanced non-small cell lung cancer treated with cancer vaccine. Mai T, Takano A, Suzuki H, Hirose T, Mori T, Teramoto K, Kiyotani K, Nakamura Y, Daigo Y. Oncol Lett. 2017;14(1):283-292.

Charaterization of the cryoablation-induced immune response in kidney cancer patients. Kato T, Iwasaki T, Uemura M, Nagahara A, Higashihara H, Osuga K, Ikeda Y, Kiyotani K, Park JH, Nonomura N, Nakamura Y. Oncoimmunology. 2017;6(7):e1326441.

Characterization of the T-Cell Receptor Repertoire and Immune Microenvironment in Patients with Locoregionally Advanced Squamous Cell Carcinoma of the Head and Neck. Saloura V, Fatima A, Zewde M, Kiyotani K, Brisson R, Park JH, Ikeda Y, Vougiouklakis T, Bao R, Khattri A, Seiwert T, Cipriani N, Lingen M, Vokes E, Nakamura Y. Clin Cancer Res. 2017;23(16):4897-4907.

Characterization of the B-cell receptor repertoires in peanut allergic subjects undergoing oral immunotherapy. Kiyotani K, Mai TH, Yamaguchi R, Yew PY, Kulis M, Orgel K, et al. J Hum Genet. 2017; doi: 10.1038/s10038-017-0364-0

Clinical significance of T cell clonality and expression levels of immune-related genes in endometrial cancer. Ikeda Y,Kiyotani K, PY Yew, Sato S, Imai Y, Yamaguchi R, et al. Oncology Reports. 2017; doi: 10.3892/or.2017.5536.

Intratumoral expression levels of PD-L1, GZMA, and HLA-A along with oligoclonal T cell expansion associate with response to nivolumab in metastatic melanoma. Hiroyuki Inoue, Jae-Hyun Park, Kazuma Kiyotani, Makda Zewde, Azusa Miyashita, Masatoshi Jinnin, et al. Oncoimmunology. 2016; 30;5(9):e1204507.>

Myasthenic crisis and polymyositis induced by one dose of nivolumab. Kimura T, Fukushima S, Miyashita A, Aoi J, Jinnin M, Kosaka T, et al. Cancer Sci. 2016; 107(7):1055-8.

Clonal expansion of antitumor T cells in breast cancer correlates with response to neoadjuvant chemotherapy. Park JH, Jang M, Tarhan YE, Katagiri T, Sasa M, Miyoshi Y, et al. Int J Oncol. 2016; 49(2):471-8.

Characterization of the T cell repertoire by deep T cell receptor sequencing in tissues and blood from patients with advanced colorectal cancer. Tamura K, Hazama S, Yamaguchi R, Imoto S, Takenouchi H, Inoue Y, et al. Oncol Lett. 2016; 11(6):3643-3649.

Characterization of T-cell Receptor Repertoire in Inflamed Tissues of Patients with Crohn's Disease Through Deep Sequencing. Chapman CG, Yamaguchi R, Tamura K, Weidner J, Imoto S, Kwon J, et al. Inflamm Bowel Dis. 2016; 22(6):1275-85.

The importance of immunopharmacogenomics in cancer treatment: Patient Selection and Monitoring for Immune Checkpoint Antibodies. N Choudhury, Y Nakamura. Cancer Science 2016; 107(2):107-15.

Low T-cell Receptor Diversity, High Somatic Mutation Burden, and High Neoantigen Load as Predictors of Clinical Outcome in Muscle-invasive Bladder Cancer. NJ Choudhury, K Kiyotani, KL Yap, A Campanile, T Antic, PY Yew, et al. Eur Urol Focus. 2015; 2405-4569

Immunopharmacogenomics. Y Nakamura. Springer. 2015

Quantitative characterization of T-cell repertoire in allogeneic hematopoietic stem cell transplant recipients. PY Yew, H Alachkar, R Yamaguchi, K Kiyotani, H Fang, KL Yap, HT Liu, et al. Bone Marrow Transplant. 2015; 50(9):1227-34.

Characterization of T Cell Repertoire of Blood, Tumor and Ascites in Ovarian Cancer Patients using Next Generation Sequencing. M Jang, PY Yew, K Hasegawa, Y Ikeda, K Fujiwara, GF Fleming, et al. Oncoimmunology. 2015; 14;4(11): e1030561.

Highly Clonal Regulatory T cell population in Follicular Lymphoma–Inverse Correlation with the diversity of CD8+ T cells. X Liu, G Venkataraman, J Lin, K Kiyotani, S Smith, M Montoya, et al. Oncoimmunology. 2015; 3;4(5):e1002728.

Quantitative T cell repertoire analysis by deep cDNA sequencing of T cell receptor α and β chains using next-generation sequencing (NGS). H Fang, R Yamaguchi, X Liu, Y Daigo, PY Yew, C Tanikawa, K Matsuda, et al. Oncoimmunology. 2014; 3(12):e968467.

Ultradeep targeted sequencing of circulating tumor DNA in plasma of early and advanced breast cancer.Chin YM, Takahashi Y, Chan HT, Otaki M, Fujishima M, Shibayama T, et al. Cancer Sci. 2020; 19. doi: 10.1111/cas.14697.

Detection of Circulating Tumor DNA in Patients of Operative Colorectal and Gastric Cancers. Suzuki T, Suzuki T, Yoshimura Y, Yahata M, Yew PY, Nakamura T, et al. Oncotarget. 2020; 11:3198-3207.

Clonal Hematopoiesis in Liquid Biopsy: From Biological Noise to Valuable Clinical Implications. Chan HT, Chin YM, Low SK, Nakamura Y. Cancers 2020; 12(8): 2277. doi:10.3390/cancers12082277

Clinical significance of clonal hematopoiesis in the interpretation of blood liquid biopsy.　Chan HT, Nagayama S, Chin YM, Otaki M, Hayashi R, Kiyotani K, et, al. Mol Oncol. 2020; doi: 10.1002/1878-0261.12727.

Breast cancer: The translation of big genomic data to cancer precision medicine. Low SK, Zembutsu H, Nakamura Y. Cancer Sci. 2017; doi: 10.1111/cas.13463